1. Introduction {#s0005}
===============

Drug interaction is an important medical issue as it can reduce or facilitate the effect of drugs and cause side effects in patients receiving multiple drug therapy ([@b0005]).

Some adverse drug interactions had fatal consequences and caused the withdrawal of popular medications from the market ([@b0010], [@b0015]).

In clinical practice, there is an important gap between what is theoretically known about DDIs and appropriate management of patients, especially in the elderly who do usually require polypharmacy for co‐morbidities ([@b0020]).

On one hand, the number of prescribed drugs is a recognized independent risk factor for serious adverse drug reactions (ADRs) in the elderly ([@b0025], [@b0030]), a vulnerable population with age‐related changes in pharmacokinetic and pharmacodynamic parameters, concomitant comorbidities and organ impairments, which increase the risk of hospitalization and mortality ([@b0035]). On the other hand, only a fraction of DDIs (that are preventable according to the drug mechanism of action) are clinically important (i.e. they require therapy adaptation and/or they can result in ADRs), and only a minority can be actually avoided by safely removing the potential precipitant agent. In addition, the clinician\'s perception of the clinical relevance of DDIs is not fully appreciated, thus underestimating relevant risk when multiple drugs are co‐administered ([@b0040], [@b0045], [@b0120]).

Most of the evidence about fatal ADRs caused by DDIs comes from case reports or case series ([@b0050], [@b0055], [@b0060]).

The high prevalence of DDI in large-scale European epidemiological studies ([@b0065], [@b0070]) necessitates a more responsible conduct of pharmacotherapy by clinicians to prevent their adverse effects.

The scientific publications describe works that confirm the efficiency of the use of trainings for physicians on the need to monitor patients when prescribing clinically significant interactions. The research group of Italian scientists evaluated influence of the educational campaign for general practitioners on the number of clinically significant interactions of drugs in elderly patients with polypharmacy. They obtained a reduction in the majority of common Drug Interactions, in particular, associated with non-steroidal anti-inflammatory drugs, and a reduction in polypharmacy in prescriptions ([@b0075]). The opposite result was obtained from clinical pharmacists in the USA, the study of which did not demonstrate a positive effect on reduction of the level of potential hazardous DDI prescription ([@b0080]). "Republican Center for Health Development" of the Ministry of Healthof the Republic of Kazakhstan ("RCHD") informs the following: According to paragraph 3 of Article 33 of the Code, health care providers are guided by clinical protocols when providing medical assistance ([@b0085]). RCHD of the Ministry of Healthcare of the Republic of Kazakhstan recommends to use the online resource Drug Interactions (FDA). In most countries of the world, researchers used it to analyze drug interactions in ongoing therapy in hospital patients and in primary outpatient practice. Attempts to clarify the DDI issues made scientists develop complex measures ([@b0090], [@b0095]), including educational interventions among doctors, pharmacists, creation of algorythms for use of significant DDI, development of reference books ([@b0100], [@b0105]).

Studies show that doctors\' knowledge of the potentially significant DDI they prescribe is usually poor in such a serious issue of clinical pharmacology as potentially dangerous drug interactions ([@b0110]). These results are supported by other studies ([@b0045], [@b0120]) and underscore the need to develop systems that warn clinicians on the prescription of clinically adverse interactions.

The lack of data on the study of the state of pharmacotherapy in the Republic of Kazakhstan, especially in the issues of drug interactions in emergency medical care hospitals, the lack of data on the effect of educational interventions on these indicators, was the reason for such research.

1.1. Aim of the study {#s0010}
---------------------

The aim of this research was to study the prevalence and structure of potentially dangerous major grade DDI using the automated electronic resource Drug Interaction (FDA) and to evaluate the effect of educational interventions on the state of pharmacotherapy in the Emergency Hospital.

Ethical approval {#s0015}
----------------

The research work was approved by the bioethical committee of the West Kazakhstan Marat Ospanov State Medical University (MoM No. 15 dated 24.11.2016). Informed consent was not required because the review of retrospective Drug-Drug Interactions alert logs and prescriptions did not involve individually identifiable data of any sort.

2. Methods {#s0020}
==========

2.1. Study design {#s0025}
-----------------

The study was conducted in two stages: the first stage (pharmacoepidemiological cross-sectional study) is a retrospective analysis of the pharmacotherapy of patient records in Emergency Hospitals in the West Kazakhstan from 01.01.2014 to 31.12.2014. The prevalence and structure of Major DDI at Emergency Care Hospitals of Aktobe, Uralsk, Atyrau cities were studied.

Major DDI were identified using Drug Interaction Checker source (FDA). The prevalence of Major DDI and their structure were studied.

Data on age and field of patients, diagnoses, complications, duration of stay in the hospital, prescribed drugs was gathered.

All drugs were classified under the international anatomical-therapeutic classification. In case of combination drugs containing a combination of active substances, each of substances was treated separately.

The following was calculated: percentage of patients with DDIs; percentage of patients with at least one DDI; the number of combinations involving Major.

The DDI structure is described by the most frequent particular drug combinations.

2.2. Stage 1 (systematic random selection study) {#s0030}
------------------------------------------------

Selection of stage 1 was formed by systematic random selection (each 3rd case history from the general list of patients of the Departments).

Inclusion criteria: stay in the hospital for more than 24 h, prescription of more than 2 drugs, age from 18 years-old.

Exclusion criteria: stay in the intensive care department for more than 3 days, patient 'age younger than 18, interactions with acetylsalicylic acid (Aspirin Cardio, Cardiomagnyl, Thrombo ass) in a dose that has antiaggregant effect (325 mg) were not considered. Acetylsalicylic acid in online checkers creates DDI of all 3 grades with most of cardiological drugs, producing dominant effect on the DDI structure, masks other drug interactions, and therefore we decided to exclude the drug from the list of interacting drugs.

2.3. Stage 2 (controlled study) {#s0035}
-------------------------------

A set of educational measures to promote pharmacotherapy in the Cardiology Departments of the Emergency Care Hospitals of Aktobe city was developed and introduced at the second stage, after which the effect of these interventions was assessed.

The complex of educational interventions developed in 2015 included: (1) a local clinical guideline for the prevention of adverse clinical outcomes of potentially dangerous drug interactions in the cardiac practice; (2) a training program for doctors, named "Monitoring potentially dangerous drug interactions in cardiac practice"; (3) algorithms for the prevention of the clinical outcomes of potentially dangerous drug interactions.

In both Hospitals, identical groups of drugs were used (angiotensin-converting enzyme inhibitors, beta-blockers, aldosterone blockers, anticoagulants, antiaggregants, proton-pump inhibitor, etc.). The drug form of both Hospitals was formed from similar International Names (INN) groups. This allowed us to compare the results of prevalence trends and the structure of potentially dangerous medicinal products after educational interventions.

In 2016, training seminars were held on the prevention of adverse effects of potentially DDI in the Cardiology Department of the Emergency Hospital of Aktobe.

Educational activities in the hospital of emergency medical care in Aktobe:

Block 1: Educational introductory reports for the Aktobe Emergency Hospital on the following topics:1.Polyparmacy -- definitions, concepts2.Adverse reactions3.Drug Interactions

2 blocks of educational seminars were held separately for the doctors of the interventional cardiology of the emergency hospital, informing the doctors with leaflet algorithms, introducing a local clinical protocol "Algorithms for preventing adverse clinical consequences of potentially dangerous drug interactions into cardiological practice"

Themes of the workshops 2:1.Clinically significant drug interactions.

Drug interactions that increase the risk of hyperkalemia. Action algorithm2.Clinically significant drug interactions.

Drug interactions that increase the risk of hemorrhagic complications. Algorithm action.3.Clinically significant drug interactions. Drug interactions with the risk of alleviating/reducing the effect of co-prescribed medication. Algorithm action.4.Clinically significant drug interactions. Drug interactions that increase the risk of heart rhythm disorders. Algorithm action.

2.4. Statistical analysis {#s0040}
-------------------------

All statistical analyses were performed using the Statistical 10 software. The study population was described with percent for categorical variables and with average, standard deviation (SD), medians, range and interquartile interval for continuous variables. Confidence interval (95% CI) was calculated for all category variables 95%. The normality of the variables distribution was verified using the Kolmogorov-Smirnov test. The relationship between continuous variables was established with the Pearson correlation. A P-value below 0.05 was considered significant.

To compare the mean values in two selections (Stage 2), the t-Student or Mann-Whitney test was used for the quantitative variables depending on distribution.

3. Results {#s0045}
==========

3.1. Stage 1 {#s0050}
------------

[Table 1](#t0005){ref-type="table"} shows the quantitative distribution of the analyzed patient records.Table 1Number of patient records analyzed at stage 1 of the research.Number of records of in-patientsAktobe cityUralsk cityAtyrau cityTotalCardiology250250230730Neurology250250250750Therapy250100105455Surgery223240139605  Total9738407242537

We found that Major DDI, revealed retrospectively with the Drug Interaction automated system, occurred in all four Departments and were mainly due to the prescription of cardiovascular drugs.

Wherein, Major DDI made 53.8% in the Cardiology Departments significantly higher than in other Departments (neurology: 18%, therapy − 11.9%, surgery − 2.7%, *P* \< 0.05).

The most common Major DDI were combinations of spironolactone with angiotensin converting enzyme (ACE) inhibitors and potassium chloride, enoxaparin and fondaparinux with clopidogrel, ACE inhibitors with potassium chloride.

Among all the DDI, the risk of hyperkalemia was the highest with a 35.1% (95% CI 31.6--38.6), followed the hemorrhagic syndrome with 27.1% (95% CI 23.9--30.5). Significantly fewer cases of DDI were found with the risk of fatal arrhythmia (4.9%; 95% CI 3.5--6.7) and the risk of decreasing the clopidogrel effect (4.1%; 95% CI 2.7--5.8). The toxicity of digoxin increased in the 2% of patients (95% CI 1.3--3.5).

3.2. Stage 2 {#s0055}
------------

### 3.2.1. Condition of pharmacotherapy of the regional Cardiology center of Uralsk city {#s0060}

In 2017, a repeated analysis of Cardiology Department patient records of Aktobe (72) and Uralsk (70, the comparison group) was conducted to evaluate educational interventions.

Groups of cardiac patients in the city of Uralsk and the city of Aktobe were comparable in age, main and concomitant clinical diagnoses, complications ([Table 2](#t0010){ref-type="table"}).Table 2Records Characteristics of patient records analyzed at stage 2 of the research.Uralsk cityAktobe cityN7072Age of patientsfrom 31 to 91 yearsfrom 30 to 90 yearsThe average age62.3 (11.3)62.4 (13.6)Men60%62.5%Women40%37,5%The duration of stay in the hospitalfrom 4 to 14 daysfrom 6 to 18 days  *Clinical diagnosis*Myocardial infarction64.3% (95%CI 51.9--75.4)62.8% (95%CI 50.3--73.6)Stable angina pectoris4.3% (95%CI 0.9--12)6.2% (95%CI 2.3--15.5)Arterial hypertension15.7% (95%CI 8.1--26.4)17.2% (95%CI 8.9--27.3)Cardiac rhythm disturbance5.7% (95%CI 1.6--13.9)5.2 (95%CI 1.5--13.6)Cardiomyopathy10% (95%CI 4.1--19.5)8.6% (95%CI 3.1--17.3)

In 2017, in total, 12 types of potentially dangerous combinations of drugs were revealed, which were administered 50 times of the regional cardiology center of Uralsk city.

Potentially dangerous DDI occurred in 29 patients − 51.4% (95% CI 49.8--53.8). One patient could have from 1 to 6 Major-combinations. At least 1 Major DDI occurred in 19 patients (27.1%), more than 1 in 10 patients (14.3%).

The most common were combinations of potassium chloride with ACE inhibitors, spironolactone with ACE inhibitors, spironolactone with potassium chloride. The dose of spironolactone was 50 mg, herewith there was no laboratory control over the potassium level in case of the relevant combinations in all the medical records.

Also amiodarone + warfarin DDI was present with a risk of hemorrhagic syndrome, and in this case it is recommended to twice reduce the dose of an indirect warfarin anticoagulant.

Amiodarone + ciprofloxacin DDI was revealed, which involves the risk of arrhythmia, this combination should be avoided.

Conspicuous is that such Major DDI with the risk of hemorrhagic syndrome as warfarin + clopidogrel, fondaparinux + clopidogrel, enoxaparin + fondaparinux, was accompanied by constant laboratory monitoring of hemostasis system (coagulation, prothrombin index, activated partial thromboplastin time, international normalized attitude) every 3--5 days in pharmacotherapy of patients.

Almost all patients received the following combinations of drugs: clopidogrel + pantoprazole, which indicates that the doctors of Uralsk city followed proposed protocols for treatment of coronary heart disease, The list of additional drugs recommends proton pump inhibitor -- pantoprazole, but not omeprazole). Coadministration with proton pump inhibitors (omeprazole) may reduce the cardioprotective effects of clopidogrel ([@b0115]).

### 3.2.2. Condition of pharmacotherapy of cardiology department of the Emergency Care Hospital of Aktobe city {#s0065}

In 2017 of the Emergency Care Hospital of Aktobe city in total, 10 types of potentially dangerous combinations of drugs were revealed, which were administered 43 times.

Potentially dangerous DDI occurred in 22 patients − 42.2% (95% CI 40.2--45.3). One patient could have from 1 to 6 Major-combinations. At least 1 Major DDI occurred in 10 patients (13.9%), more than 1 in 12 patients (16.7%).

The most common were combinations of potassium chloride with angiotensin converting enzyme (ACE) inhibitors, spironolactone with ACE inhibitors, spironolactone with potassium chloride. The dose of spironolactone was 25 mg, herewith there was no laboratory control over the potassium level in case of the relevant combinations in 20 patients. Potassium in blood was determined, glomerular filtration rate by the Cockcroft-Gold formula was calculated for the remaining 20 patients with DDI, dangerous in terms of hyperkalemia before prescription of these drugs combinations. And the dose of spironolactone was corrected by a decrease to 25 mg per day depending on the level of potassium in the blood. The emergency care hospital of Aktobe city submitted request for spironolactone in a dose of 25 mg in advance to implement the developed algorithms for monitoring the undesirable consequences of potentially dangerous DDI.

DDI with the risk of hemorrhagic syndrome were fully monitored for bleeding. Almost all patients were monitored for hemostatic system. Only in 3 cases, when warfarin + enoxaparin, clopidogrel + fondaparinux, enoxaparin + warfarin were administered together laboratory parameters were not monitored.

In case of amiodarone + warfarin DDI, the dose of warfarin was reduced, which is a positive point.

DDI with the risk of arrhythmia was prescribed 1 time. The dose of digoxin was corrected by twice decrease in 1 patient with administered DDI dangerous in terms of arrhythmia (amiodarone + digoxin).

As for clopidogrel + pantoprazole DDI, which was administered to 10 patients, its administration was recommended by acute coronary syndrome treatment of 2016, and additionally with the algorithm we developed. Request for pantoprazole in a dose of 20 and 40 mg was also submitted for its implementation.

[Table 3](#t0015){ref-type="table"} shows the doctors\' commitment to monitoring Major drugs interactions, according to the developed and introduced algorithms for the prevention of adverse clinical consequences of potentially dangerous drugs interactions.Table 3Risks of Major DDIs in the departments of cardiology in Aktobe, %.Possible consequences20142017p% of patientsRisk of hyperkalemia28.119.1\<0,01Risk of hemorrhagic syndrome19.111.3\<0,01Risk of fatal arrhythmia2.91.2\<0,01Risk of clopidogrel effect decrease2.11.4\<0,01Risk of toxicity of digoxin10.4\<0,01

When comparing the results by such an indicator as potentially hazardous DDI at Uralsk Cardiological center we observed its statistically insignificant decline by from 52.8% in 2014 to 51.4%, i.e. by 1.4% in 2017 due to decrease in prescritption of such DDI as clopidogrel + omeprazole, due to monitoring of the hemostatic system against the background of DDI with the risk of hemorrhagic syndrome, due to the correction of the dose of digoxin with a certain combination with warfarin.

Conspicuous is the lack of control over possible signs of hyperkalemia in case of DDI with the risk of hyperkalemia. Although the treatment section of chronic heart failure treatment protocol clearly indicates these recommendations. There is no doctors\' concern about this risk among doctors.

In Aktobe, a significant decrease in drug interaction was observed (OR 0.235, 95% CI 0.13--0.42).

[Table 3](#t0015){ref-type="table"} shows the most common Major drug combinations indicating also possible consequences for a patient.

When comparing the results of Major DDI in the Emergency Care Hospital of Aktobe city, a conspicuous decrease was observed. In fact, Major DDI significantly decreases from 60.4% of 2014 to 42.2% of 2017, (−18.2%, *P* \< 0.05). As shown in [Fig. 1](#f0005){ref-type="fig"} the conducted educational interventions led to a decrease in the level of Major DDI in the Cardiology of Aktobe (OR: 0.45; 95% CI 0.247--0.82). In Uralsk, there was any decrease in drug interactions (OR 0.9, 95% CI 0.5--1.6).Fig. 1The Trend of Major Drug-Drug Interactions after interventions in Aktobe city in 2017 (before and after) and in Uralsk city (without educational intervention). ^a^ -- Difference between Major DDI in 2014 and 2017 in Aktobe city (*P* \< 0.05).

4. Discussion {#s0070}
=============

We studied the effect of educational interventions on the state of pharmacotherapy in the Emergency Hospital of West Kazakhstan.

Our pharmacoepidemiological study revealed very high level of Major DDI in the Cardiology Departments, significantly exceeding the levels found in the developed countries of the world. Our findings were significantly higher than those from the cardio-resuscitative Departments of the United States, where only the 20.5% of drug interactions are potentially dangerous when using an online checker Lexi-Interact and Micromedex interaction ([@b0125]). Our data are comparable with those of Jamaica researchers, where the prevalence of potentially dangerous drug interactions in the University Medical Clinic was the 49.8%, when using an online checker Drug Interactions Checker database of Drugs.com ([@b0130]).

Since researchers use different online checkers to identify drug interactions with different levels of evidence, it is difficult to compare the results objectively.

It is of note that the prevalence of drug interactions found in the present study was comparable to literature. In one of the multidisciplinary Hospitals in Russia, Drug Interaction (FDA) revealed a 59.5% of potentially DDI in the Cardiology Department ([@b0135]). Potentially widespread dangerous drug associations are those between spironolactone and perindopril; clopidogrel and omeprazole; amlodipine and simvastatin.

According to literary data, conducted abroad, we see different effects. The use of INTERCheck(®) was associated with a significant reduction in potentially inappropriate medications (PIMs) and new-onset potentially severe DDI. Computerized Prescription Support System (CPSSs) combining different prescribing quality measures should be considered as an important strategy for optimizing medication prescription for elderly patients ([@b0140]).

Study O\'Sulliva et al. indicated that drug-related problems are prevalent in older Irish hospitalized inpatients and that a specially developed structured pharmacist review of medication intervention supported by a computerized decision support systems can improve both the appropriateness and accuracy of medication regimens of older hospitalized inpatients ([@b0145]).

This e-learning educational program had no clear effect on the quality of drug prescription and clinical outcomes in hospitalized elderly patients. Given the high prevalence of PIMs and potential DDI recorded in the frame of this study, other approaches should be developed in order to improve the quality of drug prescription in this population ([@b0150]).

A national education program aimed at general practitionerss was successful in improving prescribing for hypertension. Lessons learned will be applied in evaluation of future National dispensing programs and are also applicable to analysis of other interventions aimed at influencing prescribing behavior ([@b0155]).

Literature data on measures to improve pharmacotherapy and the results of the study have led us to develop and implement educational interventions ([@b0045], [@b0120]).

The identified problems prompted us to improve the state of pharmacotherapy by developing algorithms for the prevention of hazardous drugs. Specifically, the complex of educational interventions was developed for cardiologists, because the most often Major DDI were encountered in the appointment of combinations of cardiovascular drugs. As a result, it was registered a significant decrease in the number of Major DDI at the Emergency care Hospital of Aktobe city. In 2014, doctors prescribed combinations of drugs with the risk of hyperkalemia and hemorrhagic complications, or with risk of arrhythmia, without monitoring the condition of patients. In 2017, after informing about the prevention of adverse clinical outcomes of DDI, doctors completely excluded contraindicated DDI, by monitoring the functions of patients\' bodies and adjusting doses of drugs administered together.

Thus, our study demonstrated the effect of doctors training and involvement of administrative resources to support changes in drug list with regard to the frequencies of DDI at the Emergency Care Hospital of Aktobe city as compared to Uralsk city (OR 0.45, 95% CI 0.25--0.82).

The doctors\' adherence to follow the algorithms for the prevention of Major DDI was provided by the ability of medical personnel to check the presence of Major drug interactions in the Drug Interaction (FDA) online checker using cell phones, computers, which was introduced as a tool for DDI evaluation. Also, the positive point was the availability of printed prevention algorithms placed on the desks of staff rooms.

The latest Cochrane review concluded that 'It is unclear whether interventions to improve appropriate polypharmacy, such as pharmaceutical care, resulted in clinically significant improvement' ([@b0160]). Our study deserves attention, especially considering that not all DDI can be avoided. Depending on the underlying clinical conditions, many drugs are intentionally prescribed by doctors at the same time, since it is assumed that the expected benefit exceeds the theoretical risk of DDI. These potentially interacting prescriptions are justified by adequate risk minimization measures, such as clinical and laboratory monitoring.

The main tool in our study was Drug Interactions. Check of DDI confirmed the well-known need to create a Kazakhstani database on clinically identified drug interactions. This requires further, more extensive pharmacoepidemiological studies.

Enhancing providers' knowledge of pharmacotherapy can help reduce the rate of prescribing potentially interacting medications. This is due to the fact that the main mechanism of interaction is revealed. Providing an algorithm of actions for certain drugs helps the doctor to monitor the patient\'s condition (clinic, laboratory control).

It would be interesting to study the survival of doctors\' knowledge 1 year after the provision of educational interventions.

4.1. Limitations {#s0075}
----------------

Limitation of this study is the retrospective design and the lack of analysis of inpatient records with lethal outcome. Therefore, we plan future researches not only to assess drugs interactions, but also to reveal problems associated with their use, which can be manifested clinically or in laboratory.

The negative point of our study was that no questioning of doctors was conducted on the subject of knowledge on drug interactions.

5. Conclusion {#s0080}
=============

We revealed that among the Departments of Emergency Hospitals in Western Kazakhstan, Major DDI were most often found in the Cardiology Departments. The most common Major DDI were combinations of cardiovascular drugs leading to hyperkalemia and hemorrhagic syndrome. Dangerous combinations of drugs were: spironolactone, angiotensin-converting enzyme inhibitors, enoxaparinum natrium, natrii fondaparinuxum, clopidogrel, potassium chloride and [a]{.ul}ngiotensin II receptor blockers.

The implementation of educational pharmacotherapy programs decreased the number of Major DDI in the Cardiology department of Emergency Hospitals.
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